Tenderwize
Back to tender search

Open-House Discount Contracts for Eculizumab (including gMG and NMOSD indications)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 377 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03b - Eculizumab (inkl. der Indikation gMG und NMOSD)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

No guaranteed volume or purchase commitment from the health insurance funds; contracts are discount agreements without...

The tender is explicitly not a public procurement under EU directives; legal recourse lies with social courts, not proc...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply of pharmaceutical product Eculizumab including indications gMG and NMOSD
  • Conclusion of discount contracts under §130a Abs. 8 SGB V
Show full summary

Open-House procedure for discount contracts (Rabattverträge) according to § 130a Abs. 8 SGB V for the active substance Eculizumab including indications generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). The procedure is open to all qualified pharmaceutical entrepreneurs. Contracts have a fixed maximum duration until 31 August 2027, with possible start from 1 April 2026. No estimated value is provided. The tender is not a public procurement under EU directives; it is an Open-House model with no negotiation. Submission is possible at any time until the contract end.

Risks

No guaranteed volume or purchase commitment from the health insurance funds; contracts are discount agreements without...

The tender is explicitly not a public procurement under EU directives; legal recourse lies with social courts, not proc...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG
  • Registered office in Germany, EU, or EEA
  • Valid marketing authorization for the product or entitlement to market

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria applicable.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House Discount Contracts for Eculizumab (including gMG and NMOSD indications)

Conclusion of drug discount contracts for Eculizumab (including gMG and NMOSD) under an Open-House procedure. All qualified pharmaceutical entrepreneurs can join at any time during the contract period.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Mar 2026 - Aug 2027

Category

Pharmaceutical products

Award Criteria

No award criteria applicable.

Deadline

Deadline Aug 30, 2027

Procurement Details

Publication date
24 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
133422-2026

Documents (1)

Similar tenders